In last trading session, Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) saw 2.89 million shares changing hands with its beta currently measuring 0.19. Company’s recent per share price level of $1.96 trading at -$0.02 or -1.01% at ring of the bell on the day assigns it a market valuation of $499.14M. That closing price of MRVI’s stock is at a discount of -489.8% from its 52-week high price of $11.56 and is indicating a premium of 15.31% from its 52-week low price of $1.66.
For Maravai LifeSciences Holdings Inc (MRVI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.07 in the current quarter.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) trade information
Upright in the red during last session for losing -1.01%, in the last five days MRVI remained trading in the red while hitting it’s week-highest on Tuesday, 05/13/25 when the stock touched $1.96 price level, adding 16.42% to its value on the day. Maravai LifeSciences Holdings Inc’s shares saw a change of -64.04% in year-to-date performance and have moved -5.31% in past 5-day. Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) showed a performance of 13.29% in past 30-days.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 60.8% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -155.1% in reaching the projected high whereas dropping to the targeted low would mean a loss of -155.1% for stock’s current value.
Maravai LifeSciences Holdings Inc (MRVI) estimates and forecasts
This year revenue growth is estimated to fall -24.91% from the last financial year’s standing.
13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 47.46M for the same. And 13 analysts are in estimates of company making revenue of 50M in the next quarter. Company posted 73.4M and 65.2M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -64.27% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -179.73% while estimates for its earnings growth in next 5 years are of -15.97%.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI)’s Major holders
GTCR LLC is the top institutional holder at MRVI for having 20.15 million shares of worth $144.27 million. And as of 2024-06-30, it was holding 14.8334 of the company’s outstanding shares.
The second largest institutional holder is 12 WEST CAPITAL MANAGEMENT LP, which was holding about 13.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.7254 of outstanding shares, having a total worth of $94.59 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 3.7 shares of worth $7.24 million or 2.57% of the total outstanding shares. The later fund manager was in possession of 3.07 shares on Dec 31, 2024, making its stake of worth around $6.02 million in the company or a holder of 2.13% of company’s stock.
